President Biden is confirming the biopharma industry’s worst fears with his proposal to expand the Medicare price negotiation program established by the Inflation Reduction Act to drugs even earlier in their lifecycle. The plan is included in the president’s federal budget proposal for 2024, to be formally unveiled on 9 March.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?